Invokana vs Jardiance
Side-by-side comparison of Invokana and Jardiance — mechanism, indications, safety, trials, sponsor, and pricing.
At a glance
| Invokana | Jardiance |
|---|
| Generic name | CANAGLIFLOZIN | Jardiance |
|---|
| Sponsor | Johnson & Johnson | University of Louisville |
|---|
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor | — |
|---|
| Molecular target | Sodium/glucose cotransporter 2 | Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2 |
|---|
| Modality | Small molecule | Small molecule |
|---|
| Phase | FDA-approved | FDA-approved |
|---|
| Therapeutic area | Metabolic | Metabolic |
|---|
| First approval | 2013 | — |
|---|
Mechanism of action
| Invokana | Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption. |
|---|
| Jardiance | — |
|---|
Approved indications
Invokana
- Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
- Diabetes mellitus type 2
Jardiance
- Chronic heart failure
- Diabetes mellitus type 2
Common side effects
Invokana
- Female genital mycotic infections
- Urinary tract infections
- Increased urination
- Thirst
- Constipation
- Nausea
- Vulvovaginal pruritus
- Fatigue
Jardiance
- Urinary tract infections
- Female genital mycotic infections
- Upper respiratory tract infection
- Dyslipidemia
- Increased urination
- Arthralgia
- Male genital mycotic infections
- Nausea
Further reading